The Myeloma 2017 meeting, held in Edinburgh, UK, saw more focus on epigenetic contributors to multiple myeloma (MM) than ever before, indicating a shift in the outlook and technological capabilites to research these factors in greater detail. In this interview, Felipe Prosper Cardoso, MD, of the University of Navarra, Pamplona, Spain, discusses the new studies highlighted at the meeting that were investigating the epigenetics of MM, including the CoMMpass study (NCT01454297), which is collecting the DNA methylation pattern profiles of its wide range of participants. Dr Prosper Cardoso highlights the benefits that a greater epigenetic understanding could have on the field of MM.
Myeloma 2017: an epigenetic research boom
